EOLSのチャート
EOLSの企業情報
| symbol | EOLS |
|---|---|
| 会社名 | Evolus Inc （エボラス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 エヴォルス(Evolus Inc.)は医療美容会社である。同社は医師および美容処置・治療法を提供することに重点を置く。また、自費の美容市場を提供することに焦点を当てる。製品候補であるPrabotulinumtoxinA（DWP-450）は大規模かつ成長的美容市場のニーズに対応する注入可能な900キロダルトンのボツリヌス毒素タイプである。同社は医師と患者にDWP-450による提案を提供する。OnabotulinumtoxinA（BOTOX）は米国にある神経毒素認可900kDaボツリヌス毒素A型複合体である。 エボラスは米国の医療審美企業。医師および患者に審美・美容手術や治療法での広範な選択肢を提供する。また、自己負担における医療市場に注力する。主な候補薬には、市場でニ―ズの高い900キロダルトン分子形態のA型ボツリヌス毒素注射剤「DWP-450」などがある。本社所在地はカリフォルニア州ア―バイン。 Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. |
| 本社所在地 | 17901 Von Karman Avenue Suite 150 Irvine CA 92614 USA |
| 代表者氏名 | Vikram Malik ヴィクラム・マリク |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 949-284-4555 |
| 設立年月日 | 41214 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | － |
| url | www.evolus.com |
| nasdaq_url | https://www.nasdaq.com/symbol/eols |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -18.51500 |
| 終値（lastsale） | 16.43 |
| 時価総額（marketcap） | 438270102.13 |
| 時価総額 | 時価総額（百万ドル） 438.27010 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 411.15510 |
| 当期純利益 | 当期純利益（百万ドル） -17.56000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Evolus Inc revenues was not reported. Net loss increased from $6.3M to $22.6M. Higher net loss reflects Revaluation of contingent royalty obliga increase from $0K to $9.1M (expense) General and Administrative - Balancing v increase from $1.8M to $6.8M (expense) Stock-based Compensation in SGA increase from $232K to $2.9M (expense). |
EOLSのテクニカル分析
EOLSのニュース
Evolus (NASDAQ:EOLS) Price Target Raised to $18.00 at Truist Financial 2023/05/28 08:42:10 The AM Reporter
Evolus (NASDAQ:EOLS – Get Rating) had its target price boosted by equities researchers at Truist Financial from $14.00 to $18.00 in a research note issued to investors on Friday, The Fly reports. Truist Financial’s price objective points to a potential upside of 105.01% from the stock’s current price. A number of other brokerages have also […]
This Analyst Likes Evolus As ''Top Play In Aesthetics'' 2023/05/10 18:27:21 Benzinga
Evolus Inc (NASDAQ: EOLS ) will be the exclusive U.S. distributor for five dermal fillers currently in late-stage development from Symatese, a French regenerative medical solutions company . The addition expands the company''s total addressable U.S. market by 70% by adding a $1.6 billion U.S. filler market opportunity to the existing $2.3 billion aesthetic neurotoxin market. Both markets are expected to nearly double by 2028. The company has raised its 2028 revenue outlook to $700 million, with revenue expectation for the organic growth of Jeuveau to $500 million remaining unchanged. Evolus will pay Symatese €16.2 million, including an upfront payment of €4.1 million and … Full story available on Benzinga.com
Evolus, Inc. (EOLS) Q1 2023 Earnings Call Transcript 2023/05/10 02:53:01 Seeking Alpha
Evolus, Inc. (NASDAQ:NASDAQ:EOLS) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ETCompany ParticipantsDavid Erickson - VP, IRDavid Moatazedi - President and CEORui Avelar - CMO and…
Evolus: Q1 Earnings Insights 2023/05/09 20:15:15 Benzinga
Evolus (NASDAQ: EOLS ) reported its Q1 earnings results on Tuesday, May 9, 2023 at 04:05 PM. Here''s what investors need to know about the announcement. Earnings Evolus missed estimated earnings by 73.33%, reporting an EPS of $-0.26 versus an … Full story available on Benzinga.com
Evolus GAAP EPS of -$0.26 misses by $0.01, revenue of $41.7M beats by $1.18M 2023/05/09 20:08:18 Seeking Alpha
Evolus press release (EOLS): Q1 GAAP EPS of -$0.26 misses by $0.01.Revenue of $41.7M (+23.0% Y/Y) beats by $1.18M.Evolus continues to expect total net revenues for the full year 2023…
Evolus, Inc. (EOLS) Q4 2022 Earnings Call Transcript 2023/03/09 02:36:02 Seeking Alpha
Evolus, Inc. (NASDAQ:NASDAQ:EOLS) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ETCompany ParticipantsDavid Erickson - Vice President of Investor RelationsDavid Moatazedi -…
Evolus GAAP EPS of -$0.23 misses by $0.02, revenue of $43.65M misses by $0.17M 2023/03/08 21:12:35 Seeking Alpha
Evolus press release (EOLS): Q4 GAAP EPS of -$0.23 misses by $0.02.Revenue of $43.65M (+25.9% Y/Y) misses by $0.17M.Outlook: Evolus continues to expect total net revenues for full…
Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update 2023/03/08 21:05:00 Business Wire
NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus reports financial results for the fourth quarter and full year ended December 31, 2022 and provides a business update
Evolus Q4 2022 Earnings Preview 2023/03/07 18:38:17 Seeking Alpha
Evolus (EOLS) is scheduled to announce Q4 earnings results on Wednesday, March 8th, after market close.The consensus EPS Estimate is -$0.14 and the consensus Revenue Estimate is $43.82M…
Preview: Evolus''s Earnings 2023/03/07 16:02:35 Benzinga
Evolus (NASDAQ: EOLS ) is set to give its latest quarterly earnings report on Wednesday, 2023-03-08. Here''s what investors need to know before the announcement. Analysts estimate that Evolus will report an earnings per share (EPS) of $-0.15. Evolus bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next … Full story available on Benzinga.com
"Extra-Strength" Formulation of Jeuveau Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance 2023/01/28 13:00:00 Wallstreet:Online
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today presented interim data from its Phase II clinical study evaluating an "extra-strength" formulation for extended duration of Jeuveau (prabotulinumtoxinA-xvfs), its flagship neurotoxin product, at the 2023 International Master Course on Aging Science (IMCAS)
Evolus Receives Regulatory Approval for Nuceiva in Australia 2023/01/23 14:00:00 Wallstreet:Online
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that the Australian Therapeutic Goods Administration (TGA) has provided regulatory approval for Nuceiva (prabotulinumtoxinA)▼, a neurotoxin dedicated exclusively to aesthetics. Nuceiva was approved for the temporary improvement in the appearance
Evolus Receives Regulatory Approval for Nuceiva® in Australia 2023/01/23 14:00:00 Business Wire
NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces that the Australian Therapeutic Goods Administration (TGA) has provided regulatory approval for Nuceiva®.
Why Evolus Shares Jumped This Week 2023/01/20 18:54:32 The Motley Fool
The company said it expects to turn a profit in the fourth quarter.
Here''s Why This Analyst Seems Highly Convinced With Evolus'' Outlook 2023/01/19 18:15:34 Benzinga
Evolus Inc (NASDAQ: EOLS ) issued fourth-quarter 2022 and full-year 2022 revenues of $43.6 million, up 26% Y/Y and approximately $148.6 million, up 49%, respectively. Additionally, the company issued revenue guidance for the full-year 2023 of $180 million - $190 million and expects non-GAAP operating income to be positive in the fourth quarter of 2023 . The company has set a 2028 revenue target of $500 million, a 22% CAGR. With a Buy rating, Mizuho has raised the